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Glutamyl aminopeptidase (APA) is an M1 family membrane-bound ectoenzyme that is a target for the development of 
antihypertensive and anticancer agents. Bestatin is a natural product described as a classical inhibitor of metallo-
aminopeptidases. Although the IC50 value of bestatin vs human APA has been reported, the mechanism of inhibition is 
unknown. In the present contribution, we demonstrated that bestatin is a non-competitive (α>1) inhibitor of porcine APA 
(pAPA), with a Ki value of 31.59 µM (α=3.7). A model of the bestatin-pAPA complex predicted that bestatin binds to pAPA 
similarly to porcine aminopeptidase N (pAPN). The interaction involved catalytic and chelating residues conserved in the M1 
family. Additionally, a salt bridge with R877 and a hydrogen bond interaction with T346, both key residues for APA specificity 
for N-terminal acidic residues were identified. These residues and E213, which forms a hydrogen bond interaction with bestatin, 
are not conserved in human and porcine APN. The extension of the in silico analysis to amastatin and bestatin analogs 
probestin, and phebestin, which are APA inhibitors, indicated that they may interact with the same residues. The results indicate 
that bestatin analogues currently reported to inhibit APN are dual inhibitors of APA and APN and that some APA residues 
could be targeted to improve inhibitor selectivity. 
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Introduction 
Aminopeptidase A (APA, EC 3.4.11.7) is a M1 
family (Clan MA(E)) mammalian type II integral 
membrane zinc-containing metallopeptidase that 
hydrolyzes peptides with a N-terminal acidic residue. 
In the enzymes of this clan, the Zn
2+
 atom is linked to 
the protein through two His residues, which are part of 
the HEXXH consensus sequence. In addition to the His 
residues, the catalytic Zn
2+
 is coordinated by a water 
molecule and a third residue, Glu, located at least 14 
residues after the carboxyl terminus of the HEXXH 
sequence
1,2
. APA monomer molecular weight is 109 
kDa for the human isoform and 108 kDa for the 
porcine isoform
1
. APA's S1 pocket is structured to 
accommodate acid residue side chains, hydrolyzing 
N-terminal aspartic and glutamic residues
3
. In addition 
to the catalytic Zn
2+
, APA binds Ca
2+
, an association 
that increases its enzymatic activity. This enzyme is 
widely distributed in mammalian tissues and 
constitutively expressed by the nervous system and by 
proximal tubule cells
4,5
. APA performs fundamental 
functions in a wide range of physiological processes. It 
participates in the metabolism of angiotensin II and the 
formation of angiotensin III, one of the main effector 
peptides of the renin-angiotensin-aldosterone system in 
the central nervous system, making it an important 
regulator of blood pressure
2,3,6,7
. In addition, it is 
involved in pathophysiological processes such as the 
development of Alzheimer's disease, 
glomerulosclerosis, and the progression of cancer. It is 
associated with the development of renal neoplasms, 
malignant trophoblasts, renal choriocarcinoma, and 
colorectal cancer
8-12
. APA is thus a current target for 






Bestatin is a natural product, a classical inhibitor of 
metallo-aminopeptidases from the M1 and M17 families, 
with antitumoral and antiplasmodial effects
2,14-16
. Bestatin 
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porcine neutral aminopeptidase (APN)
15
. This enzyme is 
the most extensively studied member of the M1 family 
of aminopeptidases and catalyzes the cleavage of neutral 
and basic amino acids from the  
N-terminus of protein or peptide substrates
2
. APN is a 
current target for the development of antihypertensive 
and anticancer agents
14
. Although structural and kinetic 
studies describe the interaction of bestatin with human 
APA
3
, there is no mechanistic study that establishes the 
type of inhibition of mammalian APA by bestatin. Since 
porcine kidney APA (pAPA) has biochemical and 
functional properties similar to those of its human 
orthologue
17
, the authors studied the type of inhibition of 
pAPA by bestatin using a kinetic approach and predicted 
structural determinants of their interaction. The authors 
identified for the first time that the inhibition is non-
competitive (α>1). According to modelling data, various 
non-conserved residues as targets to improve the 
selectivity of bestatin analogues for APA vs other 
members of the M1 family are proposed. 
 
Materials and Methods 
 
Materials and reagents 
Microsomes containing pAPA were prepared as 
previously described
18
. The chromogenic synthetic 
substrate of pAPA, L-Glutamyl-p-nitroanilide (L-Glu-
pNA), and bestatin were purchased from Bachem. The 
remaining reagents were of analytical grade. A 
Genesys 10 UV light passage cuvette 
spectrophotometer, Thermo Electron Corporation, was 
used for Enzyme Activity (EA) assays of pAPA.  
 
Porcine APA enzymatic activity 
Enzymatic activity of microsomal pAPA  
(0.1 mg/mL) was determined using the specific 
chromogenic synthetic substrate L-Glu-p-NA in buffer 
Tris-HCl 50 mM pH 8.0, 1 mM of CaCl2, 0.1% of Triton 
X100 (Buffer A), to complete a final assay volume of 1 
mL, as previously described
17
. The use of the specific 
acidic substrate, and the presence of calcium in the 
system, allowed us to specifically determine the activity 
of APA and the effect of bestatin, on this enzyme 
present in the complex mixture of the microsomal 
preparation. 
 
In vitro inhibition of pAPA activity by bestatin: pre-incubation 
time and dose-response 
Bestatin was prepared as a stock solution of 10 mM 
in DMSO and diluted to obtain the desired range of 
concentrations in Buffer A. The preliminary effect of 
bestatin on pAPA was tested at 1, 10, 100 µM to identify 
the range of inhibition. Pre-incubation time for 
equilibrium was determined by enzyme incubation with 
20 µM of bestatin for 0, 1, 5, 10, 30 or 60 min, before 
the addition of L-Glu-p-NA. The dose-response effect of 
bestatin was determined by quantifying the decrease of 
activity in aliquots pre-incubated with the inhibitor (1 to 
500 µM) for 30 minutes at 37 °C (n=4)
19
. The IC50 value 
(half maximal inhibitory concentration) was determined 
by nonlinear regression of all the data of residual activity 
from the dose-response curve using the IC50 equation 
included in the software GraphPadPrism 9.0.  
 
Kinetic mechanism of inhibition of pAPA by bestatin 
Since the IC50 value of bestatin vs pAPA was higher 
than 10
-7 
M, a Michaelis-Menten approach was followed 
to study the kinetic mechanism of classical reversible 
inhibition. Enzyme assays were conducted at increasing 
L-Glu-pNA concentration (0.18-1.75 mM) and 5-100 
µM bestatin (n=4). Enzyme and inhibitor were pre-
incubated at 37 °C for 30 minutes to attain equilibrium. 
The data were transformed and fitted to the Lineweaver-
Burk (LB) model for diagnosis of the mechanism and to 
determine the slope and Y-axis intercept (1/Vmax app) of 
the line at each inhibitor concentration. With the primary 
data of intercepts and slopes, two secondary plots were 
used, as recommended by Copeland
19
: a) a Dixon plot of 
1/Vmax app as a function of inhibitor concentration, for 
determination of the αKi value (X intercept) and b) a plot 
of the LB slopes as a function of inhibitor concentration 
for determination of the Ki value (X intercept). 
Combining information from these two secondary plots 
allows the determination of both inhibitor dissociation 




Structural modelling of pAPA:inhibitor complexes 
Since human and porcine APAs have a high degree of 
sequence identity (~80% overall, ~100% for active site 
residues), we modelled the complexes between 
inhibitors and pAPA. Considering that bestatin interacts 
similarly with the human and porcine enzymes, we used 
Modeller to obtain the possible complexes by extracting 
and satisfying distance restraints automatically
20
. The 
structure of human APA (PDB ID: 4KXB) in complex 
with bestatin was used as a template. A similar strategy 
was used for modelling the pAPA: amastatin complex 
using the human APA: amastatin structure (PDB ID: 
4KX8). The complexes with bestatin derivates phebestin 
and probestin were obtained by using the structure of 
human APA (PDB ID: 4KXB) in complex with bestatin 
as a template; phebestin and probestin were aligned to 
bestatin bound in the APA active site; then, Modeller 
was used for generating the complex between these 




ligands and pAPA by extracting and satisfying distance 
restraints automatically
20
. In all the cases, an energy 
minimization step using the “Minimize Structure” 
module from Chimera software
21 
was performed. Zinc 
and atoms belonging to the coordinating residues were 
kept fixed during the minimization process; other 
parameters were kept as default. Finally, the quality of 





using SAVES6.0 online server 
(https://saves.mbi.ucla.edu/). Models had a high overall 
quality factor (>90), which characterizes the amount and 
quality of the non-bonded interactions between different 
atom types (Table 1). Poor quality regions were far from 
the active site, and we concluded they should not affect 
the modeling of the enzyme: substrate interaction (Fig. 
S1). On the other hand, the compatibility of an atomic 
model (3D) with its amino acid sequence (1D) was high 
(>96%) (Table 1). 
 
Generation of the pAPA:L-Glu-pNA complex 
A 3D structure of L-Glu-pNA substrate bound to the 
porcine APA active site was generated by docking. The 
structure of human APA bound to glutamate was used as 
template to assure glutamate side chain was properly 
oriented into APA’s S1 site. AutoDock4Zn was used for 
docking
24
 through AMDock program
25
. The grid maps 
were calculated with AutoGrid. The grid dimensions 
were 18 Å × 18 Å × 18 Å with grid spacing 0.375 Å and 
grid centre defined at the centre of mass of Zn atom.  
L-Glu-pNA was kept flexible in the grid box while the 
protein was kept rigid. Other docking parameters were 
kept as default. 
 
Generation of the terciary complex: docking of bestatin to the 
pAPA:L-Glu-pNA enzyme:substrate complex 
To obtain the predicted structure of the terciary 
complex, the enzyme: substrate structure was used as a 
receptor in bestatin docking. Bidimensional structures 
(2D) of bestatin in Structure Data File format were 
used to generate the 3D structure by using Avogadro
26
. 
Docking was performed as described before, keeping 
bestatin flexible while the enzyme: substrate complex 
was kept rigid. The grid maps were calculated with 
AutoGrid. The grid dimensions were 21 Å × 21 Å × 18 
Å with grid spacing 0.375 Å and grid centre defined at 
the centre of mass of L-Glu-pNA substrate. 
 
Sequence analysis 
The multiple sequence alignment of porcine APA 
(AMPE_PIG), human APA (AMPE_HUMAN), human 
APN (AMPN_HUMAN), porcine APN (AMPN_PIG), 
and human endoplasmic reticulum aminopeptidase 1 
(ERAP1_HUMAN) was performed using the Clustal W 
software
27
. The multiple alignments were manually 
parsed by analyzing the gaps, conserved amino acid 







Kinetic characterization of microsomal pAPA inhibition by 
bestatin 
At 0.25 mM substrate concentration pAPA was 
dose-dependently inhibited by 1-100 µMbestatin  
(Fig. S2a); 30 minutes pre-incubation with 20 µM 
bestatin was sufficient to attain equilibrium (Fig. S2b). 
Dose-response studies were performed using  
30 minutes pre-incubation. Bestatin effect on APA 
 
 
Fig. 1 — Biochemical analysis of the mode of interaction of bestatin with pAPA; a): Dose-response curve (data are individual values 
(n=4)); the 2D structure of bestatin is shown, b): Lineweaver-Burk plot for diagnosis of the modality of pAPA inhibition by bestatin (Data 
are mean±SD, n=4) 
Table 1 — Quality assessment of APA: inhibitor models with 
ERRAT and Verify3D algorithms 
Model ERRAT * Verify3D ** 
APA:bestatin 94.9 96.02 
APA:amastatin 90.1 96.11 
APA:phebestin 94.7 96.13 
APA:probestin 95.0 96.10 
  * Overall quality factor  
** % of residues that have an averaged 3D-1D score ≥  recommended 
score (0.2) 




activity was dose-dependent (Fig. 1a). IC50 was 20.58 
µM (95% CI: 16.74 to 25.39 µM, r
2
=0.9903), 
suggesting bestatin acts as a classical inhibitor. The 
kinetic mechanism of inhibition was studied using the 
Lineweaver-Burk (LB) approach
19
. The pattern of 
straight lines in the double-reciprocal plot is the 
signature for a typical non-competitive (α>1) inhibition 
(Fig. 1b). This means that bestatin displays a binding 
affinity for both the free enzyme and the enzyme-
substrate binary complex. This mode of inhibition is 
also referred to in the literature as “mixed” inhibition 
since it manifests at increasing inhibitor concentration 
as a combination of decreased Vmax (indicative of a 
reduction in the catalytic efficiency) and increased KM 
(indicative of a reduction in the substrate affinity). Two 
secondary plots, LB slopes vs inhibitor concentration 
(Fig. S3a) and 1/Vmax vs inhibitor concentration  
(Fig. S3b) led to a Ki value of 31.59 µM with α=3.7 for 
the pAPA-bestatin interaction. This α value indicates 
that bestatin binds free pAPA with almost 4-fold higher 
affinity than the enzyme: substrate complex. 
 
Bioinformatic studies of the porcine APA interaction with 
bestatin and other natural inhibitors 
To figure out how bestatin inhibits pAPA, we 
analyzed the binding mode of the inhibitor to the 
porcine enzyme obtained by homology modelling. We 
addressed inhibitor interactions with residues enrolled 
in catalysis,substrate-binding and other putative 
subsites. The modelling of the pAPA: bestatin 
complex (Fig. 2a) showed that the inhibitor 












 implicated in catalysis. 
These interactions support the non-competitive type 
of inhibition identified by the kinetic approach and 
the effect on Vmax at increasing inhibitor 
concentration.  
The S1 pocket of human APA is well suited to 
accommodate the side chains of acidic residues. Our 
analysis showed a salt bridge interaction between the 
C-terminal carboxylate of bestatin and the 




 in human 
APA, R
878
 in mouse APA), a key residue in the 
interaction of the substrate with the APA active site. 
This interaction between bestatin and R
887
supports the 
competitive component of the identified non-
competitive inhibition (α>1). Additionally, we 
detected a hydrogen bond interaction with T
346
, which 
plays a key role in the substrate specificity of APA for 
N-terminal acidic amino acids. Bestatin also forms a 
hydrogen bond interaction with pAPA E
213 
that is not 
conserved in human and porcine APN. 
To better understand the non-competitive inhibition 
profile, it was critical to address inhibitor interactions 
with residues enrolled in the substrate-binding pocket 
and other putative subsites. Therefore, we docked the 
substrate in the active site of pAPA and subsequently 
generated the terciary complex APA: substrate: 





were spotted in the terciary complex, 
the number of interactions of bestatin with the enzyme: 
substrate complex was lower than with the free enzyme 
(Fig. S4). This is expected for a non-competitive  
(α>1) inhibition profile in which bestatin binds free 
pAPA with almost 4-fold higher affinity than the 
enzyme: substrate complex. 
Taking into account these findings, the authors 
extended the in silico structural analysis to other 
natural M1 family inhibitors, such as the natural 
bestatin analogues probestin (IC50 vs pAPA 19.0 µM)
29
 
and phebestin (IC50 vs pAPA 20 µM)
30
, and amastatin 
(Ki vs hAPA 74.0 nM)
3
. There is no information 
regarding the structural basis of porcine APA inhibition 
by these molecules. Phebestin (Fig. 2b) and probestin 
(Fig. 2c) accommodated in a pose similar to that of 
bestatin, with similar interactions. Phebestin made an 
additional cation-pi interaction with the lateral group of 
R
881
. Amastatin fit into the S3’subsite of pAPA, 
forming a salt bridge with R
376
. However, the binding 
of amastatin (Fig. 2d) was slightly different to that of 
bestatin, probestin and phebestin, with a higher number 





Bestatin is a very well known inhibitor of M1 and 
M17 metallo aminopeptidases
2
, but knowledge about its 
effect on APA was limited to some biochemical and 
structural data for its interaction with human APA
3
. 
There was no mechanistic study that establishes the type 
of inhibition of mammalian APA by bestatin. In the 
present contribution, we identified by kinetic assays the 
mechanism of inhibition of bestatin vs porcine APA. 
Dose-response studies revealed IC50 values in the 
micromolar range, suggesting bestatin acts as a classical 
inhibitor. This IC50 value is in the same order as that of 
other bestatin derived inhibitors of the M1 family, 
although for most of them there are no data regarding 
APA inhibition
14,31,32
. The Lineweaver-Burk approach 
applied to the kinetic data strongly supports a non-
competitive inhibition (α > 1). This mechanism was 
previously shown for bestatin vs porcine kidney APN 




and human placental APN
16
, as well as for bestatin vs 
Escherichia coli APN (PepN)
32
. The Ki value of 31.59 
µM determined for the pAPA-bestatin interaction is 
lower than previously reported for the human APA  
(Ki: 75 µM) using a similar substrate, but a different 
kinetic approach
3
. In the latter case, the Ki value for 
the human enzyme was determined from the IC50 
value assuming a competitive mode of inhibition
3
. In 
this work, the crystallographic structure of human 
APA bound to bestatin was experimentally 
determined and the authors found that bestatin targets 
the active site and partially binds the S1 pocket. Since 
the S1 pocket is the primary determinant for substrate 
specificity, the authors assumed a competitive 
inhibition mechanism (i.e., total blockade of substrate 
binding), without any kinetic experimental validation. 
However, our experimental data provide clear 
evidence of non-competitive inhibition (a>1), 
 
 
Fig. 2 — Predicted binding mode of pAPA complexes with natural inhibitors and alignment of contact residues among several M1 
aminopeptidases. Ligands have been represented as sticks (C: magenta, N: blue, O: red) while APA active site residues as lines (C: cyan, N: blue, 
O: red). The Zn atom is represented as a grey sphere. Hydrogen bond interactions are represented as red dashed lines, salt bridges as yellow 
dashed lines, pi-pi stacking as green dashed lines, cation-pi interactions as orange dashed lines, and Zn coordination as grey dashed lines. For 
clarity, residues interacting only via van der Waals bonds are represented as cyan curved lines. Uniprot codes: porcine APA (AMPE_PIG); 
human APA (AMPE_HUMAN), human APN (AMPN_HUMAN), porcine APN (AMPN_PIG), human endoplasmic reticulum aminopeptidase 
(ERAP1_HUMAN). (a) pAPA: bestatin (BES) complex; (b) pAPA:phebestin (PHB) complex; (c) pAPA: probestin (PRB) complex; (d) pAPA: 
amastatin (AMA) complex. 




indicating that impairment of substrate binding 
(increment of KM) by bestatin only contributes 
partially to the mechanism. 
 
To understand the non-competitive inhibition profile 
identified for bestatin vs pAPA, we modelled inhibitor 
interactions with residues enrolled with different subsites 
involving substrate binding and catalysis. APN and APA 
share a common catalytic mechanism despite their 
modest sequence similarity
3,33
. The modelling of the 
pAPA: bestatin complex shows that the inhibitor 
accommodated in a pose similar to that previously 
predicted for the pAPN: bestatin complex
15
, including 











). These residues are highly 
conserved inside the M1 family; chelation of zinc ions 
through a zinc-binding group is the most common mode 
of action for inhibitors targeting metallo 
aminopeptidases
14,31,34
. Thus, these data support the non-
competitive type of inhibition identified by the kinetic 
approach. 
 
The S1 pocket accommodating the P1 side chain of 
ligands differs markedly between APN and APA, 
consistent with their different substrate specificities. The 
S1 pocket of human APA is well suited to accommodate 
the side chains of acidic residues; i.e., the P1 carboxylate 
side chain forms a strong salt bridge with R
887
 and a 
hydrogen bond with T
356 
in human APA, and similarly 
for R
878
 in mouse APA. These energetically favourable 
interactions are consistent with the high activity that 
mammalian APA exerts on substrates with glutamate at 
the P1 site
3,35
. In line with this, our analysis showed 




. This last 
residue plays a key role in the substrate specificity of 
APA for N-terminal acidic amino acids by ensuring the 
optimal positioning of the substrate during catalysis
36
. 
The sequence analysis of aminopeptidases belonging to 





residues should improve the selectivity and 
potency of APA inhibitors regarding other M1 family 
members, as demonstrated for EC33 [(S)-3-amino-4-
mercapto-butyl sulfonic acid] 
37




Additionally, bestatin forms a hydrogen bond interaction 
with E
213
, a residue that is not conserved in human and 
porcine APN, which suggests another clue for the design 
of selective inhibitors of APA vs APN. 
 
Based on the findings with bestatin, we extended the 
in silico structural analysis to other natural metallo 
aminopeptidases inhibitors. In general, probestin and 
phebestin showed similar interactions to that of bestatin. 
In addition, phebestin interacted with the lateral group of 
R
881
, a residue not conserved in human and porcine 
APN and another member of the M1 family, human 
endoplasmic reticulum aminopeptidase 1. Amastatin 
fits into the S3’subsite of pAPA, as previously shown 
for its experimentally determined binding to hAPA
3
, 
with a higher number of hydrogen bonds and an 
interaction with N
878
, a residue not conserved in the 
M1 family. The high number of interactions of 
amastatin with pAPA is in accordance with a Ki value 
for hAPA at least three orders of magnitude lower 
than the Ki value for bestatin-pAPA. These results 
suggest mechanisms by which bestatin analogues 
currently reported as inhibitors of APN
31,32,34,39,40 
are 
probably also inhibitors of APA.  
There are few examples of non-competitive inhibitors 
in the literature and clinical use, including against M1 
family aminopeptidases like APN and APA
15,17
. 
Compared to competitive inhibition, non-competitive 
inhibition is advantageous when physiological context 
exposes the target enzyme to high substrate 
concentrations
19
. The mode of inhibition of bestatin and 
analogues vs pAPA is relevant in the context of the 
development of new antihypertensive agents targeting 
brain renin-angiotensin system
7
, and to treat cancers like 





Micromolar bestatin inhibits the activity of porcine 
APA through a non-competitive (α>1) mechanism. The 
Ki value is 2-3 fold lower than previously reported for 
human APA. The discovery of a non-competitive 
mechanism is of biomedical relevance for APA 
inhibitor applications. Additionally, the predictions that 
bestatin, probestin and phebestin interact with the 
R
877
and that amastatin interact with N
878
 (both non-
conserved residues inside the M1 family), may be 
useful for the design of bestatin and amastatin 
analogues selective for APA vs other M1 family 
members. 
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